ScholarLens Back to search
2005•Chinese New Drugs JournalRequires access

Anidulafungin;a new echinocandin antifungal agent

FU De-xing

Open publisher page 0 citations

Abstract

Anidulafungin(Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent activity against Aspergillus and Candida spp.Anidulafungin is a noncompetitive inhibitor of(1,3)-beta-D-glucan synthase within fungal cells.Its features include a larger distribution volume and potentially broader and more potent antifungal activities than other echinocandins.Anidulafungin is in Phase Ⅲ stage of clinical studies in USA.This paper introduces the mechanism,pharmacodynamics,pharmacokinetics and clinical therapeutics of anidulafungin.

About this research paper

What this paper is about

Anidulafungin(Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent activity against Aspergillus and Candida spp.Anidulafungin is a noncompetitive inhibitor of(1,3)-beta-D-glucan synthase within fungal cells.Its features include a larger distribution volume and potentially broader and more potent antifungal activities than other echinocandins.Anidulafungin is in Phase Ⅲ stage of clinical studies in USA.This paper introduces the mechanism,pharmacodynamics,pharmacokinetics and clinical therapeutics of anidulafungin.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Anidulafungin(Vicuron Pharmaceuticals) is a new echinocandin antifungal with potent activity against Aspergillus and Candida spp.Anidulafungin is a noncompetitive inhibitor of(1,3)-beta-D-glucan synthase within fungal cells.Its features include a larger distribution volume and potentially broader and more potent antifungal activities than other echinocandins.Anidulafungin is in Phase Ⅲ stage of clinical studies in USA.This paper introduces the mechanism,pharmacodynamics,pharmacokinetics and clinical therapeutics of anidulafungin.

Key concepts: Anidulafungin, Echinocandin, Echinocandins, Pharmacology, Antifungal, Pharmacodynamics, Pharmacokinetics, Medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Anidulafungin;a new echinocandin antifungal agent — Research Paper | ScholarLens